👀 Ones to watch: The MOST undervalued stocks to buy right nowSee Undervalued Stocks

China's Fosun says willing to provide BioNTech vaccines to Taiwan

Published 05/22/2021, 05:26 AM
Updated 05/22/2021, 07:25 AM
© Reuters. FILE PHOTO: Test tubes are seen in front of a displayed Biontech logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration

© Reuters. FILE PHOTO: Test tubes are seen in front of a displayed Biontech logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration

PFE
0.23%
AZN
-0.39%
MRNA
-0.74%

BEIJING (Reuters) - China's Shanghai Fosun Pharmaceutical Group Co Ltd is willing to provide Taiwan with BioNTech COVID-19 vaccines, its chairman Wu Yifang told Xinhua news agency, amid a spike in domestic infections on the island.

Fosun signed a deal with BioNTech to exclusively develop and commercialise COVID-19 vaccine products developed using BioNTech's mRNA technology in mainland China, Hong Kong, Macau and Taiwan.

BioNTech's development and distribution partner for the rest of the world is U.S. firm Pfizer Inc. (NYSE:PFE)

Wu said certain groups in Taiwan he did not name had been in touch for an emergency purchase of vaccines and the company was willing to "provide vaccine services to Taiwan compatriots".

Since last year, Fosun has been promoting vaccines for Taiwan, Wu said, adding they hope shots can arrive on the island soon to help prevent a resurgent spread of the virus.

Fosun did not immediately reply to a Reuters request for comment.

Taiwan's government has said it is talking with BioNTech rather than Fosun, and that the two sides were on the verge of announcing a deal in December when BioNTech pulled the plug.

Taiwan has implied China was to blame for the failed deal, while China has blamed Taiwan for trying to circumvent Fosun.

BioNTech said in February it planned to provide the vaccine to Taiwan, but has not provided further details and declined to comment on the progress of talks in a statement to Reuters this week.

China claims Taiwan as its own territory, and has repeatedly sparred with the island over the coronavirus pandemic. Taiwan has accused China of spreading fake news, which Beijing denies.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads.

Taiwan has received only around 700,000 vaccine doses to date, all from AstraZeneca (NASDAQ:AZN) Plc, and those are rapidly running out as it steps up vaccinations during a spike in domestic infections.

Taiwan has millions more doses on order, including from Moderna (NASDAQ:MRNA) Inc, but like many other parts of the world has faced delivery delays due to global shortages.

PFE: is this perennial leader facing new challenges?

With valuations skyrocketing in 2024, many investors are uneasy putting more money into stocks. Sure, there are always opportunities in the stock market – but finding them feels more difficult now than a year ago. Unsure where to invest next? One of the best ways to discover new high-potential opportunities is to look at the top performing portfolios this year. ProPicks AI offers 6 model portfolios from Investing.com which identify the best stocks for investors to buy right now. For example, ProPicks AI found 9 overlooked stocks that jumped over 25% this year alone. The new stocks that made the monthly cut could yield enormous returns in the coming years. Is PFE one of them?

Unlock ProPicks AI to find out

Latest comments

Cosmic DustMay 22, 2021, 17:50
Chinese jabs don't work.
Petros KazakidisMay 22, 2021, 23:32
Hiw do you know. Have you taken it and you got infected?
Kaveh SunMay 22, 2021, 17:39
Just a China political tool, vaccine is available to ‘patriots’
Petros KazakidisMay 22, 2021, 23:35
he said compatriots did he not?
Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.